Noema Pharma extends its series B funding to $147M, advancing phase 2 trials for CNS disorders like Tourette syndrome, ...

Is the key to curing the world’s most challenging diseases hidden in unlocking the power of fragmented biological data?

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

The pharma arm of Mitsubishi Chemical Group has launched a collaboration with US-based Dewpoint Therapeutics to co-develop a preclinical-stage treatment for the neurological condition amyotrophic ...

Investment in radiopharmaceuticals is ramping up as big pharma shows a growing appetite for this promising drug modality. Radiopharmaceuticals see radioactive isotopes being delivered into a target, ...